Epizyme Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Epizyme (EPZM) 6M Offering Prices at $20.75/Share
March 18, 2015 8:16 AM EDTEpizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 6,000,000 shares of its common stock at a price of $20.75 per share before underwriting discounts. All of the shares of common stock to be sold in the offering are to be sold by Epizyme. In addition, Epizyme... More
Epizyme (EPZM) to Offer 4.75M Common Shares
March 16, 2015 4:19 PM EDTEpizyme (NASDAQ: EPZM) announced that it intends to offer and sell up to 4,750,000 shares of its common stock in an underwritten public offering. Epizyme intends to grant the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock. All of the shares of... More
